EUVIMEDEUVIMED entdecken
Crossref

Janus kinase inhibitors show a longer drug survival than biologics in a real-world cohort of patients with rheumatoid arthritis – a retrospective analysis from the RHADAR database

Linus Maximilian Risser, Torsten Witte, Matthias Englbrecht, Patrick-Pascal Strunz, Matthias Froehlich, Marc Schmalzing, Michael Gernert, Peter Bartz-Bazzanella, Cay von der Decken, Kirsten Karberg, Georg Gauler, Susanna Späthling-Mestekemper und 4 weitere

Rheumatology International · 15.04.2025 · 45 (5)

DOI: 10.1007/s00296-025-05859-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rheumatology International, online erschienen am 15.04.2025. Verfasst von Linus Maximilian Risser und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Medical School Hannover, Hannover, Germany. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Janus Kinase Inhibitors, Antirheumatic Agents, Biological Products. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: RheumaDatenRhePort GbR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Numerous biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) have been approved for treating rheumatoid arthritis (RA), including Janus kinase inhibitors (JAKi), rituximab, abatacept, interleukin-6 inhibitors (IL-6i) and tumor necrosis factor inhibitors (TNFi). Real-world data regarding treatment persistence and drug survival in the time period following the approval of JAKI are limited. To investigate the persistence and drug survival of different (b/tsDMARDs) in patients with RA based on real-world data from German outpatients. We performed a retrospective analysis of RA patients in the German RHADAR database who received a newly prescribed therapy with a b/tsDMARD between January 15, 2015 and October 17, 2023. To compare drug survival, we used Cox regression analyses adjusted for age, sex and disease duration. We included 4678 patients (79.9% female, mean age 58.7 years, mean disease duration 11.7 years). TNFi (47.8%) and JAKi (29.4%) were most frequently prescribed. The five-year drug survival rate was highest for JAKi (68.3%), followed by TNFi (58.6%), IL-6i (58.6%), abatacept (55.0%), and rituximab (53.3%). Compared to JAKi, Cox regression showed a higher discontinuation risk for rituximab (HR 1.36, p = 0.015), abatacept (HR 1.46, p < 0.001), IL-6i (HR 1.20, p = 0.026), and TNFi (HR 1.29, p < 0.001). Rituximab had the highest two-year survival (70.3%) but a sharp decline afterward, with 60% of discontinuations occurring between March 2020 and July 2022. In a real-world setting in German outpatients with RA, JAKi was associated with longer drug survival than bDMARDS. There were no significant differences in treatment persistence among different bDMARDs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidJanus Kinase InhibitorsAntirheumatic AgentsBiological ProductsHumansFemaleMaleMiddle AgedRetrospective StudiesAgedDatabases, FactualGermanyAdult

Stichwörter der Autor:innen

Biological therapyDrug persistenceJanus kinase inhibitorsKaplan-Meier analysisRetrospective studiesRheumatoid arthritis

Substanzen

Janus Kinase InhibitorsAntirheumatic AgentsBiological Products

Autor:innen und Institutionen

  • Department of Rheumatology and Immunology, Medical School Hannover, Hannover, Germany.
  • Freelance Healthcare Data Scientist, Eckental, Germany.
  • Department of Internal Medicine 2, Rheumatology/Clinical Immunology, University Hospital Würzburg, Würzburg, Germany.
  • Klinik für Internistische Rheumatologie, Rhein-Maas-Klinikum, Würselen, Germany.
  • Medizinisches Versorgungszentrum, Stolberg, Germany.
  • Verein zur Förderung der Rheumatologie e.V, Würselen, Germany.

Förderung

  • RheumaDatenRhePort GbR

Zitieren

APA

Risser, L. M., Witte, T., Englbrecht, M., Strunz, P. P., Froehlich, M., Schmalzing, M., Gernert, M., Bartz-Bazzanella, P., von der Decken, C., Karberg, K., Gauler, G., Späthling-Mestekemper, S., Kuhn, C., Vorbrüggen, W., Welcker, M., & Kleinert, S. (2025). Janus kinase inhibitors show a longer drug survival than biologics in a real-world cohort of patients with rheumatoid arthritis – a retrospective analysis from the RHADAR database. Rheumatology International, 45(5). https://doi.org/10.1007/s00296-025-05859-7

Vancouver

Risser LM, Witte T, Englbrecht M, Strunz PP, Froehlich M, Schmalzing M, et al. Janus kinase inhibitors show a longer drug survival than biologics in a real-world cohort of patients with rheumatoid arthritis – a retrospective analysis from the RHADAR database. Rheumatology International. 2025;45(5). doi:10.1007/s00296-025-05859-7

BibTeX
@article{Risser2025,
  author = {Risser, Linus Maximilian and Witte, Torsten and Englbrecht, Matthias and Strunz, Patrick-Pascal and Froehlich, Matthias and Schmalzing, Marc and Gernert, Michael and Bartz-Bazzanella, Peter and von der Decken, Cay and Karberg, Kirsten and Gauler, Georg and Späthling-Mestekemper, Susanna and Kuhn, Christoph and Vorbrüggen, Wolfgang and Welcker, Martin and Kleinert, Stefan},
  title = {Janus kinase inhibitors show a longer drug survival than biologics in a real-world cohort of patients with rheumatoid arthritis – a retrospective analysis from the RHADAR database},
  journal = {Rheumatology International},
  year = {2025},
  volume = {45},
  number = {5},
  doi = {10.1007/s00296-025-05859-7}
}
Kostenlos starten →